Walgreens CEO Roz Brewer steps down after more than 2 years in the role

Walgreens CEO Roz Brewer steps down after more than 2 years in the role


Rosalind “Roz” Brewer

Jason Redmond | Afp | Getty Images

Walgreens Boots Alliance said Friday that Roz Brewer had stepped down as the company’s chief executive.

She also left the company’s board, effective Thursday. The decision was mutual, according to a news release.

Brewer and Walgreens were in a rough patch leading up to Friday’s announcement. Walgreens shares are down more than 32% this year as of Thursday’s close, as the company has struggled with a drop in demand for Covid testing and vaccines. In June, the company reported fiscal third quarter earnings that missed Wall Street expectations for the first time since July 2020. It also slashed its profit guidance for the year.

Walgreens said it is searching for a new CEO. In the meantime, Ginger Graham, the lead independent director, will work as interim chief.

A veteran of Walmart and Starbucks, Brewer had led Walgreens since March 2021. During her brief tenure, which included a sizable stretch of the Covid pandemic, the company had pursued a transition that would position Walgreens more as a health care company than a pharmacy chain.

“I am confident that WBA is on track to be a leading consumer-centric healthcare company, serving thousands of communities across the country, especially those that need access to healthcare the most,” Brewer said in Friday’s announcement.

This is breaking news. Please check back for updates.



Source

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 
Health

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.  The company also said it has filed for Food and Drug Administration approval of the daily […]

Read More
Medical supply firm Medline set to debut after biggest IPO of 2025
Health

Medical supply firm Medline set to debut after biggest IPO of 2025

U.S. medical supplies giant Medline is set to debut on the Nasdaq on Wednesday after the biggest initial public offering of the year.  The private equity-owned company priced at $29 per share on Tuesday, raising $6.26 billion in an upsized offering that finishes off a strong year for new listings and bolsters optimism about the […]

Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Health

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever.  2026 is likely the year that two new oral weight loss […]

Read More